MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code ...

MIAMI, Nov. 15, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the ...

OPKO Health, Inc. OPK recently received the FDA approval for its 4Kscore Test. Presently, this test is available at BioReference Laboratories — an OPKO Health company — via its specialty oncology and ...

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test. This test is approved for ...

OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, has announced the European launch of the 4Kscore Test, the only blood test that accurately identifies risk for aggressive ...

The 4Kscore Test was developed and validated by OPKO Lab in a 1,012 patient blinded, prospective study in the U.S. in 2014. “We are proud to now offer the 4Kscore Test to European clinicians and ...

The cash register is ringing at OPKO Health (OPK), which spells great news for investors. Last week, OPKO announced that its 4Kscore test for the detection of prostate cancer has been granted a Level ...

MIAMI, May 18, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability ...

ORLANDO, Florida — A newly available commercial blood test performs better than a commonly used online risk calculator in predicting which men with an elevated prostate-specific antigen (PSA) level ...

MIAMI, June 28, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test ...